Conclusions AFEV,%pred appears to be the most u%sefuTm'ethod of expressing bronchodilator response, both for clinical and for research purposes. Reversibility of airways obstruction in response to a bronchodilator is a continuous vaillIe and not a dicnotomous traiL. Any cut off level of a "positive" brronchodiator response is therefore arbitrary.
Assessment of a bronchodilator response is a routine procedure both in pulmonary medicine and in research. This response is primarily assessed as a tool to distinguish "mainly reversible" from "irreversible" airways obstruction, a key difference between asthma and chronic obstructive lung disease.' 2 The results of bronchodilator response tests are commonly used as a basis for classification of disease and choice of treatment by clinicians and as an inclusion criterion for studies by research workers. Despite these important functions of bronchodilator response testing, there is no agreement on how the results should be expressed." The mode of expression may depend on the reason why the test is performed.' There is also no consensus on what constitutes a "positive" response."' As a result numerous criteria are being used, for which the scientific foundation appears to be largely lacking. For example, a change in forced expiratory volume in one second (FEV1) of more than 15% of the initial level is commonly considered to signify a "positive" bronchodilator response,' although 429 group.bmj.com on June 19, 2017 -Published by http://thorax.bmj.com/ Downloaded from Brand, Quanjer, Postma, Kerstjens, Koiter, Dekhuijzen, Sluiter, and CNSLD study group several studies have reported that this criterion provides poor discrimination between patients with asthma and those with chronic obstructive lung disease'; it also increases the response in patients with a low initial FEV1.6"9 This dependence of bronchodilator response on initial FEV1 may be undesirable, especially when responses ofpatients with different initial FEVy levels are being compared. '4 Although several expressions of bronchodilator response have been discussed from a theoretical point of view in some detail,5 1 115 few comparative clinical studies have been carried out. Most studies have been confined to patients with chronic obstructive lung disease7131416; other results have been obtained in relatively small groups of patients with unstandardised treatment.17 18 We studied bronchodilator response under strictly standardised conditions in a large group of adults with obstructive airways disease, with a broad range of clinical presentations and lung function, during the baseline period of a long term multicentre trial. In this report we compare different expressions of bronchodilator response with respect to their dependence on initial FEV, and to their efficacy in distinguishing asthmatic individuals from patients with chronic obstructive lung disease.
Methods

PATIENTS
For this report we used baseline data from a multicentre trial supported by the Dutch government. The main goal of this trial is to compare the effect of three different treatment regimens (# agonist plus either placebo, anticholinergic agent, or corticosteroid, all given by inhalation) on the long term (30 months) course and outcome of obstructive airways disease. '9 We recruited 274 adult patients (aged 18-60 years) with chronic respiratory symptoms from six university hospital pulmonary outpatient clinics if they had a baseline FEVy level greater than 1-2 litres and 1-64-4-5 residual standard deviations (RSD) below the predicted value, or if their FEV1/inspiratory vital capacity (IVC) ratio was more than 1-64 RSD below the predicted value provided that total lung capacity was less than 1-64 RSD below the predicted level.20 Another selection criterion was hyperresponsiveness to inhaled histamine (the provocative concentration of histamine causing a 20% decrease in FEVy (PC20) <8 mg/ml-see below). We excluded pregnant women, patients with a history of occupational asthma or other serious diseases (for example, tuberculosis, myocardial infarction, and malignancy), patients who were taking oral corticosteroids, ,B blocking drugs, nitrates, or anticoagulants, and patients who were taking antibiotics continuously.
By using data from a standardised history we identified different clinical syndromes, closely adhering to the criteria proposed by the American Thoracic Society':
* patients reporting attacks of breathlessness and wheeze (asthmatic attacks) without chronic (that is, for more than three months a year) cough or sputum production were labelled as having asthma (n = 99, 36%); * current or former smokers without a history ofasthmatic attacks, reporting either chronic cough with or without sputum production or dyspnoea when walking quietly on level ground, or both, were included in the chronic obstructive lung disease group (n= 51, 19%); * patients with both asthmatic attacks or recurrent wheeze and chronic cough and sputum production were labelled as having asthmatic bronchitis (n = 88, 32%). In 36 subjects (13%) a clinical syndrome diagnosis could not be made from the data obtained from the history because these were either incomplete or unreliable ("no diagnosis" group).
The study protocol was approved by the medical ethics committees of all participating centres; all patients gave written informed consent. DATA 
ACQUISITION
Before entering the study patients discontinued their usual maintenance treatment for the following times: at least one month for ketotifen and antihistamines, two weeks for an inhaled corticosteroid and for sodium cromoglycate, and two days for theophyllines. For the 14 days before the present study only inhaled bronchodilators were used. These were withheld at least eight hours before measurement of lung function. All measurements were performed when subjects were clinically stable, and at least three weeks after discontinuation of a course of oral corticosteroids.
A [11) , to initial of the scatter. = -0.003 x + 0-639.
NUMBER OF RESPONDERS FOR EACH EXPRESSION
The number of patients with a "positive" response was calculated with commonly quoted cut offlevels for different expressions of the bronchodilator response. The sensitivity and specificity of these criteria in separating subjects with asthma from patients with a history of chronic obstructive lung disease was calculated (table 2). The best separation (highest likelihood ratio) of asthma from chronic obstructive lung disease was found for a AFEV1%pred of 9%.
BRONCHODILATOR RESPONSES IN DIFFERENT PATIENT GROUPS
To allow comparison of different measures of bronchodilator responsiveness with respect to their distributions among the diagnostic subgroups, parametric analysis of variance was performed for all measures of bronchodilator response except A FEV1 %[pred -init] (the distribution of this variable was so clearly nonnormal that the condition of normality for the ANOVA was obviously violated). Results are presented in table 3. The difference between groups (expressed as the F ratio of the ANOVA) was most pronounced for A SR-FEV1, AFEV1%pred, and AFEV1[l], and less clear for AFEV1%init (table 3); this was also true when non-parametric ANOVA was applied (Kruskall-Wallis procedure). Despite these differences in mean response considerable overlap in bronchodilator responses of individual cases occurred between patient groups (fig 6) . For example, the interquartile (50%) range of AFEV1%pred was 8-49-22-8 for asthma, 4-66-16 7 for asthmatic bronchitis, and 3-23-12-9 for chronic obstructive lung disease.
SPONTANEOUS CHANGES IN FEVy
The 45 patients in whom spontaneous changes in FEV1 were assessed were 
